Business Context and Reporting Period
This Form 8-K is filed by India Globalization Capital, Inc. (IGC Pharma, Inc.) on January 28, 2011, regarding events occurring between July 14, 2010, and January 28, 2011. The filing addresses a regulatory deficiency in the Company's previously filed audited financial statements for the fiscal year ended March 31, 2010, which contained a qualified audit opinion. The Company has since filed an amended Form 10-K containing an unqualified opinion.
Key Financial Metrics and Liquidity
The filing does not provide current revenue, profit, or cash flow metrics. However, it discloses specific capital raising activities that may be deemed unregistered:
- At-the-Market (ATM) Offering: Between September 7, 2010, and January 18, 2011, the Company sold 2,189,660 shares for an aggregate gross price of $1,640,004.
- December 2010 Offering: The Company sold 2,575,830 shares of common stock and warrants to purchase 858,610 shares (exercise price $0.90) for an aggregate gross purchase price of $1,545,498.
Material Changes and Regulatory Status
The primary material change is the SEC's determination that the Company's initial Form 10-K filed on July 14, 2010, was deficient due to a qualified audit opinion. Consequently:
- The Company is deemed delinquent in its filings as of July 14, 2010.
- The Company ceased eligibility to use Form S-3 for securities registration as of July 14, 2010.
- The Company is deemed ineligible to use Form S-8 for its 2008 Omnibus Incentive Plan, preventing option exercises absent an exemption.
- Registration statements for Public Warrants (IPO, September 2009, and December 2010) are ineffective for cash exercises, though cashless exercise may be available for certain warrants.
- Trading in the Company's common stock, IPO Warrants, and units on the NYSE Amex was suspended pending review.
Outlook, Risks, and Management Commentary
Management intends to file new registration statements or amend existing ones to restore eligibility for Forms S-3 and S-8 and to cover warrant exercises and stockholder resales. The Company may request relief from the Commission, though there is no assurance such requests will be granted.
Material Risks:
- Unregistered Sales: Sales of securities made after July 14, 2010, under the affected registration statements may be deemed unregistered.
- Rescission Rights: Purchasers of securities in potentially unregistered offerings may be entitled to rescission rights.
- Enforcement Actions: The Company faces potential enforcement actions, penalties, or fines from federal or state regulatory authorities.
- Market Impact: The suspension of trading and potential legal claims could have a material adverse effect on the Company.
Investor Verification Checklist
- Verify the status of the amended Form 10-K filed on January 28, 2011, and confirm the unqualified audit opinion.
- Confirm whether the NYSE Amex has resumed trading in the Company's securities.
- Monitor for new or amended registration statements (Forms S-1, S-3, S-8) filed to address the SEC's deficiencies.
- Assess the risk of rescission claims from investors who purchased shares in the ATM offering or December 2010 Offering.
- Check for any updates regarding the Company's ability to issue securities under its Stock Plan or exercise warrants.